Navigation path

Pharmaceuticals - Union Register

  

Register of orphan medicinal products


GRANTED  

Product information

5-{(1R,2R)-2-[(cyclopropylmethyl)amino]cyclopropyl}-N-(tetrahydro-2H-pyran-4-yl)thiophene-3-carboxamide monohydrochloride

EU orphan designation number: EU/3/18/2082   
Active ingredient: 5-{(1R,2R)-2-[(cyclopropylmethyl)amino]cyclopropyl}-N-(tetrahydro-2H-pyran-4-yl)thiophene-3-carboxamide monohydrochloride
Indication: Treatment of Kabuki syndrome
Sponsor: Takeda Pharma A/S
Dybendal Alle 10, 2630 Taastrup, Danmark

  

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
21/11/2018 Orphan designation EMA/OD/040/18 (2018)7791 of 19/11/2018